• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>GlaxoSmithKline PLC ADR

GlaxoSmithKline PLC ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. GSK Files Regulatory Submission in US for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD

    GSK Files Regulatory Submission in US for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD

  2. Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD

    Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD

  3. FTSE 100 pulls back as pound strengthens, but oil shares hold gains

    FTSE 100 pulls back as pound strengthens, but oil shares hold gains

  4. LONDON MARKETS: FTSE 100 Pulls Back As Pound Strengthens, But Oil Shares Hold Gains

    LONDON MARKETS: FTSE 100 Pulls Back As Pound Strengthens, But Oil Shares Hold Gains

  5. The Corporate Reputation of Pharma 2015 - The Perspective of 110 Patient Groups with an Interest in Skin Conditions - Research and Markets

    The Corporate Reputation of Pharma 2015 - The Perspective of 110 Patient Groups with an Interest in Skin Conditions - Research and Markets

  6. The Corporate Reputation of Pharma 2015-2016 - The Perspective of 139 Patient Groups with an Interest in Diabetes - Research and Markets

    The Corporate Reputation of Pharma 2015-2016 - The Perspective of 139 Patient Groups with an Interest in Diabetes - Research and Markets

  7. The Corporate Reputation of Pharma 2015-2016 - The Perspective of 111 Patient Groups with an Interest in Hepatitis - Research and Markets

    The Corporate Reputation of Pharma 2015-2016 - The Perspective of 111 Patient Groups with an Interest in Hepatitis - Research and Markets

  8. GlaxoSmithKline Starts Phase III Studies with Daprodustat

    GlaxoSmithKline Starts Phase III Studies with Daprodustat

  9. Avoid Medicare Advantage Plans

    GlaxoSmithKline GSK reported solid second-quarter results on Wednesday that were largely in line with our expectations, and we don't anticipate any changes to our fair value estimate. Sales increased 10% from the prior year driven by strong sales of asthma medicine Advair, diabetes medicine ...

  10. Low-Cost Exposure to U.S. Healthcare Firms

    This ETF holds a swath of large- and mid-cap U.S. healthcare companies.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.